This is part of an occasional series of brief Q&As with pharma newsmakers in China. This week we talked to Gregory Frost, chairman and CEO of Exuma Biotech.
What is Exuma Biotech’s origin story and why did you decide to found this company?
After nearly 15 years at Halozyme, where we developed a new technology to simplify the administration of some very impactful antibody-based medicines, I became intrigued with the challenges and complexity facing cellular therapies.
